Abstract
Sorbitol dehydrogenase (SDH), a member of the medium-chain dehydrogenase / reductase protein family and the second enzyme of the polyol pathway of glucose metabolism, converts sorbitol to fructose strictly using NAD+ as coenzyme. SDH is expressed almost ubiquitously in all mammalian tissues. The enzyme has attracted considerable interest due to its implication in the development of diabetic complications and thus its tertiary structure may facilitate the development of drugs for the treatment of diabetes sufferers. Modelling studies suggest that SDH is structurally homologous to mammalian alcohol dehydrogenase with respect to conserved zinc binding motif and a hydrophobic substrate-binding pocket. Recently, the three-dimensional (3- D) structure of a mammalian SDH was solved, and it was found that while the overall 3-D structures of SDH and alcohol dehydrogenase are similar, the zinc coordination in the active sites of the two enzymes is different. The available structural and biochemical information of SDH are currently being utilized in a structure-based approach to develop drugs for the treatment or prevention of the complications of diabetes. This review provides an overview of the recent advances in the structure, function and drug development fields of sorbitol dehydrogenase.
Keywords: sorbitol dehydrogenase, structure, function, inhibitors, ligand design
Current Medicinal Chemistry
Title: Sorbitol Dehydrogenase: Structure, Function and Ligand Design
Volume: 11 Issue: 4
Author(s): O. El-Kabbani, C. Darmanin and R. P.-T. Chung
Affiliation:
Keywords: sorbitol dehydrogenase, structure, function, inhibitors, ligand design
Abstract: Sorbitol dehydrogenase (SDH), a member of the medium-chain dehydrogenase / reductase protein family and the second enzyme of the polyol pathway of glucose metabolism, converts sorbitol to fructose strictly using NAD+ as coenzyme. SDH is expressed almost ubiquitously in all mammalian tissues. The enzyme has attracted considerable interest due to its implication in the development of diabetic complications and thus its tertiary structure may facilitate the development of drugs for the treatment of diabetes sufferers. Modelling studies suggest that SDH is structurally homologous to mammalian alcohol dehydrogenase with respect to conserved zinc binding motif and a hydrophobic substrate-binding pocket. Recently, the three-dimensional (3- D) structure of a mammalian SDH was solved, and it was found that while the overall 3-D structures of SDH and alcohol dehydrogenase are similar, the zinc coordination in the active sites of the two enzymes is different. The available structural and biochemical information of SDH are currently being utilized in a structure-based approach to develop drugs for the treatment or prevention of the complications of diabetes. This review provides an overview of the recent advances in the structure, function and drug development fields of sorbitol dehydrogenase.
Export Options
About this article
Cite this article as:
El-Kabbani O., Darmanin C. and Chung P.-T. R., Sorbitol Dehydrogenase: Structure, Function and Ligand Design, Current Medicinal Chemistry 2004; 11 (4) . https://dx.doi.org/10.2174/0929867043455927
DOI https://dx.doi.org/10.2174/0929867043455927 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DNAJ Proteins and Protein Aggregation Diseases
Current Topics in Medicinal Chemistry The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Amyloid β Accumulation Assessed with <sup>11</sup>C-Pittsburgh Compound B PET and Postmortem Neuropathology
Current Alzheimer Research Autophagy in Diabetic Retinopathy
Current Neuropharmacology S-Nitrosylation: Targets, Controls and Outcomes
Current Genomics Phosphorylated and O-GlcNAc Modified IRS-1 (Ser1101) and -2 (Ser1149) Contribute to Human Diabetes Type II
Protein & Peptide Letters Hypertension in Diabetes: Optimal Pharmacotherapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Selenium in the Therapy of Neurological Diseases. Where is it Going?
Current Neuropharmacology Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Molecular Mechanisms of Skeletal Muscle Insulin Resistance in Type 2 Diabetes
Current Diabetes Reviews Gene Therapy for Diabetes Mellitus
Current Molecular Medicine Therapeutic Approach for Neuronal Disease by Regulating Reninangiotensin System
Current Hypertension Reviews Synergic Study of α-Glucosidase Inhibitory Action of Aloin and its Antioxidant Activity with and without Camel β-Casein and its Peptides
Protein & Peptide Letters Genetics in Diabetic Retinopathy: Current Concepts and New Insights
Current Genomics Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry Astrocytes: New Targets for the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Angiotensin Receptor Blockers in Chronic Heart Failure: Clinical Implications and Molecular Mechanisms
Current Cardiology Reviews Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Molecular Mechanisms Determining Opposed Functional States of Microglia
Current Neuropharmacology Sulfonyl Group-Containing Compounds in the Design of Potential Drugs for the Treatment of Diabetes and Its Complications
Current Medicinal Chemistry